• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 23, 2015

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Researchers from the University of California at Los Angeles, the University of Southern California and Harvard University have used large-scale sequencing of prostate risk cancer genes to estimate that 42 percent of prostate cancer risk is due to rare variants. Read More

In the clinic

Aptose Biosciences Inc., of San Diego, said the FDA placed a clinical hold on the phase Ib trial of APTO-253 in patients with hematologic cancers, following the company's voluntary suspension of dosing in the study. Read More

Financings

Newron Pharmaceuticals SpA, of Milan, Italy, said it completed a private placement of 209,364 shares with an undisclosed U.S.-based biotechnology and health care specialist fund for gross proceeds of $5.4 million. The subscription price was CHF25.60 (US$25.12) per share. Under the agreement, the fund holds an option to subscribe to another 209,364 newly issued shares no later than June 30, 2016. Newron said proceeds will accelerate the advancement of the planned pivotal trial with sarizotan to treat patients with Rett syndrome. The transaction is expected to close by Nov. 25. Piper Jaffray acted as exclusive financial advisor. Read More

Other news to note

Genmab A/S, of Copenhagen, Denmark, said it achieved a $45 million milestone in its Darzalex (daratumumab) collaboration with Janssen Biotech Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson. Read More

Stock movers

Read More

Velcade successor Ninlaro wins FDA approval in fast turnaround

The FDA Friday gave a faster-than-expected nod to Takeda Pharmaceutical Co. Ltd.'s Ninlaro (ixazomib), an oral proteasome inhibitor expected to eventually replace blockbuster Velcade (bortezomib), which is set to lose patent protection later this decade. Read More

Malaysia sets five-year data protection in TPP; good news for pharma

HONG KONG – The Malaysian government is setting a five-year data protection structure for biologics in the country under the terms of the Trans-Pacific Partnership (TPP). That could mean more expensive drugs for the people and better protection for drugmakers. Read More

No downpour, but steady drizzle of FDA criticism rains on Kyndrisa parade

As Biomarin Pharmaceutical Inc. unveiled a data analysis comparing the efficacy of Kyndrisa (drisapersen) in similar patients across three randomized studies, the FDA let fly with briefing documents for Tuesday's meeting of the Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee (adcom). Read More

Samsung Bioepis lands positive CHMP opinion for Enbrel biosimilar

Plans to launch the first biosimilar of Enbrel (etanercept, Amgen Inc.) in Europe are taking a big step forward with receipt by Samsung Bioepis Co. Ltd. of a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP). Read More

NICE seeking real world data on drugs' cost effectiveness

LONDON – The UK is to apply real world evidence to decisions on whether to allow routine commissioning of expensive cancer drugs, providing a fast track to companies that offer lower prices and collect data on patient benefit for the first two years a product is on the market. Read More

The price is tight: HHS forum slugs drug thugs, wants right to negotiate

Runaway drug pricing, deductible tricks by health insurance providers to dodge payouts, and the importance of developing new therapies as weighed against what patients can afford – such topics and more were taken up during a day-long forum sponsored by the Department of Health and Human Services (HHS). Read More

Cell culture lines get broader, deeper, more reproducible

To skeptics, looking for cancer drugs by screening cell lines is the equivalent of searching for your lost wallet under a street lamp. The types of cells that can be cultured, the argument goes, are different in critical ways from those that can't, and any knowledge gleaned from them is likely to lead drug developers down a primrose path that ends in clinical failure. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe